AL8326 not checked

Advenchen Laboratories Nanjing Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
9 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“AL8326 is a novel small molecule multi-receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFr1, FGFr2, FGFr3), vascular endothelial growth factor receptor (VEGFr1, VEGFr2, VEGFr3) and Aurora-B.”In the company’s words, NCT07811232 on ClinicalTrials.gov
Tested for
Small Cell Lung Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung, Solid Tumor, Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms and 1 more
Main trialPhase 3
“This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.”In the company’s words, NCT06247605 on ClinicalTrials.gov

Other drugs for Small Cell Lung Carcinoma

All 118 drugs for Small Cell Lung Carcinoma

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2028 A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Phase 2Recruiting Dec 2027 Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Phase 1/2Recruiting 7 Nov 2029 A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Phase 1/2Not yet recruiting 1 Sep 2030 A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
Phase 1Active, not recruiting Dec 2027 A Study of AL8326 in Non-Small Cell Lung Cancer
Phase 1/2Unknown Sep 2021 A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Phase 1Unknown Dec 2022 A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects
Phase 1Unknown Dec 2023 A Phase I Study of AL8326 in Advanced Solid Tumor
Phase 1Completed 17 May 2025 A Study of AL8326 in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AL8326

Following is part of Solo: you see every change to AL8326 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in